You are here

IBS-d

Bausch takes hit in Xifaxan patent feud, potentially paving the way for Norwich's IBS-D generic

Fierce Pharma

Mon, 08/1/22 - 10:33 am

Norwich Pharmaceuticals

Urovant's lead drug disappoints in mid-stage study as first big FDA decision looms

Endpoints

Wed, 11/25/20 - 10:29 am

clinical trials

OrphoMed's IBS-D Candidate ORP-101 Receives Fast Track Designation

CP Wire

Wed, 04/25/18 - 01:09 pm

OrphoMed's IBS-D Candidate ORP-101 Receives Fast Track Designation

Wed, 04/25/18 - 09:18 am

Valeant partner Cosmo turns wannabe IBS-D rival, and it could do some sales damage: analyst

Fierce Pharma

Mon, 01/29/18 - 11:57 pm

Valeant Pharmaceuticals

Copying Valeant's Xifaxan just got 'a lot easier,' thanks to new FDA guidance: analyst

Fierce Pharma

Tue, 03/21/17 - 06:58 pm

Valeant Pharmaceuticals

Allergan's stellar Viberzi coverage bodes well for future launches: Analyst

Fierce Pharma

Mon, 06/20/16 - 09:51 pm

Salix Pharma Hits A New High On Bullish Clinical-Trial Data

Yahoo/Investors Business Daily

Wed, 07/2/14 - 12:00 am

clinical trials

Furiex irritable bowel syndrome drug succeeds in large trials

Yahoo/Reuters

Tue, 02/4/14 - 07:44 am

Furiex Pharmaceuticals

Lexicon Completes Phase 2 Study Of LX1033 In IBS-d

Yahoo

Tue, 12/3/13 - 09:26 am

Lexicon Pharmaceuticals